Home » Stocks » BIOL

BIOLASE, Inc. (BIOL)

Stock Price: $1.04 USD -0.05 (-4.59%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $1.09 +0.05 (4.81%) Jan 22, 7:59 PM
Market Cap 97.25M
Revenue (ttm) 24.44M
Net Income (ttm) -14.28M
Shares Out 81.34M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.04
Previous Close $1.09
Change ($) -0.05
Change (%) -4.59%
Day's Open 1.10
Day's Range 1.01 - 1.10
Day's Volume 34,965,996
52-Week Range 0.23 - 1.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
24/7 Wall Street - 1 week ago

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: MRO, WPRT, KERN, ORGO
InvestorPlace - 1 week ago

Biolase (BIOL) stock is flying high on Tuesday after announcing a massive deal for its dental lasers with Dental Care Alliance. The post BIOL Stock Alert: 14 Things for Potential Investors to ...

Benzinga - 1 month ago

This article is going to explain what penny stocks are and discuss four penny stocks under $1 to watch as small-cap stocks continue a hot streak this winter. First thing's first, what are penn...

Other stocks mentioned: JAGX, SENS, TNXP
Insider Monkey - 1 month ago

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through ...

PRNewsWire - 2 months ago

FOOTHILL RANCH, Calif., Nov. 13, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to participate in the Benchmark Comp...

Seeking Alpha - 2 months ago

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

FOOTHILL RANCH, Calif., Nov. 5, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release third quarter 2020 financial and ope...

PRNewsWire - 2 months ago

FOOTHILL RANCH, Calif., Oct. 27, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has made available an updated corporate presenta...

PRNewsWire - 3 months ago

FOOTHILL RANCH, Calif., Oct. 14, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced unaudited preliminary revenue results for the third quar...

PRNewsWire - 4 months ago

FOOTHILL RANCH, Calif., Sept. 11, 2020 /PRNewswire/ -- BIOLASE, Inc.

PRNewsWire - 5 months ago

FOOTHILL RANCH, Calif., Aug. 18, 2020 /PRNewswire/ -- BIOLASE, Inc.

Seeking Alpha - 5 months ago

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

FOOTHILL RANCH, Calif., Aug. 13, 2020 /PRNewswire/ -- BIOLASE, Inc.

PRNewsWire - 5 months ago

FOOTHILL RANCH, Calif., Aug. 6, 2020 /PRNewswire/ -- BIOLASE, Inc.

PRNewsWire - 6 months ago

IRVINE, Calif., July 22, 2020 /PRNewswire/ -- BIOLASE, Inc.

PRNewsWire - 6 months ago

IRVINE, Calif., July 16, 2020 /PRNewswire/ -- BIOLASE, Inc.

PRNewsWire - 6 months ago

IRVINE, Calif., July 13, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced data published in the Journal of Periodontology from a clinical ...

PRNewsWire - 6 months ago

IRVINE, Calif., July 9, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that BIOLASE CEO Todd Norbe has been invited to participate in a ...

PRNewsWire - 6 months ago

IRVINE, Calif., July 2, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), a global leader in dental lasers, today announced that the subscription period for the rights offering has commenced....

PRNewsWire - 7 months ago

IRVINE, Calif., June 22, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), a global leader in dental lasers, today provided an informational update to stockholders regarding its proposed righ...

PRNewsWire - 7 months ago

IRVINE, Calif., June 11, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the closing on June 10, 2020 of its previously announced registe...

PRNewsWire - 7 months ago

IRVINE, Calif., June 8, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has entered into a securities purchase agreement with ins...

Seeking Alpha - 8 months ago

BIOLASE Inc (BIOL) CEO Todd Norbe on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q2 2019 - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

Other stocks mentioned: DXCM, HAE, OFIX
Seeking Alpha - 1 year ago

Biolase's (BIOL) CEO Todd Norbe on Q1 2019 Results - Earnings Call Transcript

About BIOL

BIOLASE, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems to perform... [Read more...]

Industry
Medical Devices
IPO Date
Nov 13, 1992
CEO
Todd Norbe
Employees
157
Stock Exchange
NASDAQ
Ticker Symbol
BIOL
Full Company Profile

Financial Performance

In 2019, BIOLASE, Inc.'s revenue was $37.80 million, a decrease of -18.10% compared to the previous year's $46.16 million. Losses were -$17.86 million, -17.02% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for BIOLASE, Inc. stock is "Buy." The 12-month stock price forecast is 1.41, which is an increase of 35.58% from the latest price.

Price Target
$1.41
(35.58% upside)
Analyst Consensus: Buy